TARS
Tarsus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$90.78
+9.10%Margins
Gross margin
90.6%
EBITDA margin
-5.8%
EBIT margin
-8.0%
Net margin
-7.7%
FCF margin
10.2%
-13.4%
Return on equity
-7.6%
Return on assets
-11.1%
Return on invested capital
1.02x
Asset turnover
$79.7M
Cash from operations
$10
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026